13 recruiting. 13 Phase 2, 4 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Recruiting 13 |
| Phase 1 | 4 | Recruiting 4 |
| Phase 3 | 2 | Recruiting 2 |
Follow Gallbladder Neoplasms: new trials by email Literature Review of Gallbladder Neoplasms trials Research Report on Gallbladder Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 29 | 2026-11-01 | 2026-09-10 |
| Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Multicenter Prospective Phase II Study Postoperative radiotherapy, Capecitabine or S-1 - Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 92 | 2026-06-16 | 2026-06-24 |
| Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer EB-HC01 dual-target CARNK cells, Fludarabine, Cyclophosphamide - Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 30 | 2026-03-02 | 2026-06-11 |
| Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer PD-1/CTLA-4 Dual Functional Antibody, Gemcitabine, Cisplatin, Anlotinib - Bile Duct Carcinoma, Gall Bladder Cancer | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 60 | 2025-06-01 | 2025-06-17 |
| A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) BAY2927088 - Advanced Solid Tumors, HER2 Mutation | Phase 2 | Recruiting | Bayer | 111 | 2025-02-13 | 2026-10-02 |
| Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer chemotherapy with gemcitabine and oxaliplatin; small molecure TKI lenvatinib; immune-checkpoint inhibitor toripalimab. - Intrahepatic Cholangiocarcinoma (Icc), Gall Bladder Cancer | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 33 | 2024-09-01 | 2025-02-28 |
| Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors MDX2001 - Biliary Tract Cancer, Breast Cancer | Phase 1 / Phase 2 | Recruiting | ModeX Therapeutics, An OPKO Health Company | 330 | 2024-06-12 | 2026-10-15 |
| Radiation Therapy in Unresectable Gall Bladder Cancer Systemic therapy (Gemcitabine plus Cisplatin), RT, Systemic therapy (Gemcitabine plus oxaliplatin) - Gall Bladder Cancer | Phase 2 / Phase 3 | Recruiting | Tata Memorial Centre | 249 | 2024-03-07 | 2025-04-11 |
| DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations Trastuzumab, Pertuzumab - Haematological Malignancy, Colorectal Neoplasms | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-03-07 | 2025-12-02 |
| Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab - Gallbladder Cancer, Initially Unresectable | Phase 2 | Recruiting | Lu Wang, MD, PhD | 50 | 2022-12-22 | 2023-03-07 |
| Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types Atezolizumab, Tivozanib - Bile Duct Cancer, Gall Bladder Cancer | Phase 1 / Phase 2 | Recruiting | University of Florida | 29 | 2021-12-07 | 2026-07-13 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) rezatapopt, pembrolizumab - Advanced Solid Tumor, Advanced Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | PMV Pharmaceuticals, Inc | 300 | 2020-10-29 | 2026-10-02 |
| Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA gemcitabine and oxaliplatin., Afatinib - Gallbladder Carcinoma | Phase 2 | Recruiting | Shanghai Jiao Tong University School of Medicine | 102 | 2020-06-01 | 2024-10-16 |
Cholangiocarcinoma (6) · Biliary Tract Neoplasms (5) · Ovarian Neoplasms (5) · Breast Neoplasms (4) · Prostatic Neoplasms (4) · Colorectal Neoplasms (3) · Endometrial Neoplasms (3) · Pancreatic Neoplasms (3) · Bile Duct Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Esophageal Neoplasms (2) · Head and Neck Neoplasms (2) · Lung Neoplasms (2) · Sarcoma (2)
Biliary Tract Diseases (13) · Digestive System Diseases (13) · Digestive System Neoplasms (13) · Gallbladder Diseases (13) · Neoplasms by Site (13) · Neoplasms (12) · Biliary Tract Neoplasms (8) · Neoplasms by Histologic Type (8) · Adenocarcinoma (7) · Carcinoma (7) · Neoplasms, Glandular and Epithelial (7) · Adnexal Diseases (5) · Endocrine Gland Neoplasms (5) · Endocrine System Diseases (5) · Female Urogenital Diseases (5)
Gemcitabine (5) · Oxaliplatin (4) · Cisplatin (3) · 130-nm albumin-bound paclitaxel (2) · durvalumab (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Afatinib (1) · Bevacizumab (1) · Capecitabine (1) · Commerce (1) · Cyclophosphamide (1) · Disulfides (1) · Drug Therapy (1) · Fluorouracil (1) · Immunoglobulin G (1)
Bayer (1) · Beijing Biotech (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Cancer Research UK (1) · First Affiliated Hospital of Zhejiang University (1) · Lu Wang, MD, PhD (1) · ModeX Therapeutics, An OPKO Health Company (1) · Ohio State University Comprehensive Cancer Center (1) · PMV Pharmaceuticals, Inc (1) · Shanghai Jiao Tong University School of Medicine (1) · Tata Memorial Centre (1) · Tianjin Medical University Cancer Institute and Hospital (1) · University of Florida (1)
China (7) · United States (5) · Australia (2) · France (2) · Italy (2) · South Korea (2) · Spain (2) · United Kingdom (2) · Canada (1) · Denmark (1) · Germany (1) · India (1) · Japan (1) · Singapore (1) · Switzerland (1)
Leighton Elliott, MD (1) · Marc Fellous, MD (1) · Matthew Krebs, Dr (1) · Sameek Roychowdhury, MD, PhD (1) · Shivakumar Gudi, MD (1) · Tingbo Liang, MD (1) · Yingbin Liu, PHD (1)
PMID 36399037, PMID 36854604, PMID 40543428, PMID 40812353, PMID 40932470, PMID 41495607, PMID 41740031